{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:16:13Z","timestamp":1776219373817,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":709,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Clinical and Translational Science Center","award":["UL1-RR024996"],"award-info":[{"award-number":["UL1-RR024996"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.bbmt.2013.02.013","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T19:15:55Z","timestamp":1361387755000},"page":"831-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in\u00a0Multiple Myeloma"],"prefix":"10.1016","volume":"19","author":[{"given":"Tomer M.","family":"Mark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Pearse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"Van Besien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsiporah","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2013.02.013_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.02.013_bib2","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.02.013_bib3","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2010.32.5878","article-title":"Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies","volume":"29","author":"Moreau","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.02.013_bib4","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.02.013_bib5","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.02.013_bib6","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.02.013_bib7","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents","volume":"28","author":"Chanan-Khan","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.02.013_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.23546","article-title":"Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma","volume":"113","author":"Barlogie","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2013.02.013_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2005-06-2573","article-title":"Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol","volume":"107","author":"Moreau","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.02.013_bib10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","article-title":"Busulfan 12 mg\/kg plus melphalan 140 mg\/m2 versus melphalan 200 mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study","volume":"95","author":"Lahuerta","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2013.02.013_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2013.02.013_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","volume":"132","author":"Ponisch","year":"2006","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.02.013_bib13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2011.08887.x","article-title":"Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma","volume":"156","author":"Grey-Davies","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.02.013_bib14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3109\/10428194.2011.622422","article-title":"Efficacy of bendamustine in relapsed\/refractory myeloma patients: results from the French compassionate use program","volume":"53","author":"Damaj","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2013.02.013_bib15","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","article-title":"Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase I\/II open-label, dose escalation study","volume":"119","author":"Lentzsch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.02.013_bib16","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy","volume":"90","author":"Knop","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2013.02.013_bib17","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.02.013_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/CAD.0b013e3280149eb1","article-title":"A\u00a0phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors","volume":"18","author":"Rasschaert","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bbmt.2013.02.013_bib19","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.02.013_bib20","first-page":"96","article-title":"The Association of Ki67 Percent Positivity and Clinical Outcomes in the Upfront Treatment of Multiple Myeloma","author":"Mark","year":"2011","journal-title":"Haematologica [abstract]"},{"key":"10.1016\/j.bbmt.2013.02.013_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.02.013_bib22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.1998.16.4.1547","article-title":"Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma","volume":"16","author":"Desikan","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.02.013_bib23","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.02.013_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.bmt.1704424","article-title":"Activity of single-agent melphalan 220-300 mg\/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma","volume":"33","author":"Phillips","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.02.013_bib25","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood.V120.21.2009.2009","article-title":"Randomized comparison of melphalan 200 mg\/m2 v. 280 mg\/m2 as a preparative regimen for patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"120","author":"Bensinger","year":"2012","journal-title":"Blood [abstract]"},{"key":"10.1016\/j.bbmt.2013.02.013_bib26","article-title":"In\u00a0vitro and ex\u00a0vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells","volume":"278","author":"Leoni","year":"2004","journal-title":"AACR Meeting Abstracts"},{"key":"10.1016\/j.bbmt.2013.02.013_bib27","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1200\/JCO.2007.13.6028","article-title":"Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy\u2013European Blood and Marrow Transplantation Mucositis Advisory Group","volume":"26","author":"Blijlevens","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.02.013_bib28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","article-title":"Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model","volume":"38","author":"Grazziutti","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.02.013_bib29","article-title":"In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral\u00a0mucositis or related patient's burden","author":"Blijlevens","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.02.013_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbmt.2012.08.003","article-title":"A\u00a0phase 1 dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function","volume":"19","author":"Abidi","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.02.013_bib31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bmt.2008.387","article-title":"Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT","volume":"43","author":"Avivi","year":"2009","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113000980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113000980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:45:14Z","timestamp":1761057914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879113000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1083879113000980"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.02.013","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717995302.793475285","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717995302.793474247","asserted-by":"object"}]},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in\u00a0Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}